Abstract:Background Osteoporosis is a systemic skeletal disorder characterized by decreased bone density and the degradation of bone tissue microarchitecture. Ginsenoside Rg1, derived from Panax ginseng , has been a part of traditional Chinese medicine in China for centuries, particularly for treating osteoporosis. However, there remains limited research on the osteogenic potential of Rg1 within the glucocorticoid-induced osteoporosis (GIOP) model and its specific mechanisms. Purpose The primary objective of this study is to investigate the osteogenic potential of Rg1 within the GIOP model and explore the signaling pathways associated with its in vivo and in vitro effects. Methods Cell proliferation, differentiation and mineralization were evaluated by the Cell counting kit 8(CCK8) assay, alkaline phosphatase (ALP) test and Alizarin Red S staining, respectively. The qPCR technique was used to determine the relative expression of mRNA and the western blot was used to determine the relative expression of protein. In vivo experiments, spinal vertebrae staining in zebrafish larvae was accomplished by alizarin red S staining. Results Zebrafish larvae's hatching, survival, malformation, and heart rate were unaffected by 50 μM of Rg1 in vivo , while the MEC3T3-E1 cell line's proliferation was unaffected by 50 μM of Rg1 in vitro . Meanwhile, Rg1 was shown to improve osteogenic differentiation or bone formation as well as the level of mRNA expression of osteogenic markers in vivo and in vitro . Treatment with Rg1 significantly increased the expression of G protein-coupled estrogen receptor (GPER) and pAKT. In addition, the GPER inhibitor G15 could significantly reduce the mRNA and protein expression levels of GPER and phosphorylated AKT, LY294002, a PI3K/AKT pathway inhibitor, markedly suppresses the expression of phosphorylated AKT, yet shows no significant impact on GPER expression. Both G15 and LY294002 can significantly blocked the Rg1-mediated enhancement of osteogenesis capacity in the GIOP model. In contrast, when both the agonists G1 of GPER and LY294002 were added, G1 increased the relative expression of mRNA and protein of GPER, but not the expression of osteogenic capacity and osteogenic markers. Conclusions This study investigates the mineralization effects and mechanisms of Ginsenoside Rg1 both in vitro and in vivo . For the first time, we propose that Rg1 might regulate osteogenesis by modulating AKT phosphorylation through mediating GPER expression within the PI3K/AKT pathway in the GIOP model. This discovery introduces novel targets and avenues for osteoporosis treatment.

Ginsenoside Rg1 Promotes Bone Marrow Stromal Cells Proliferation Via the Activation of the Estrogen Receptor-Mediated Signaling Pathway.

Ginsenoside Rg1 facilitates neural differentiation of mouse embryonic stem cells via GR-dependent signaling pathway.

The Mechanisms of Ginsenosides Rg1 on the Proliferation of Bone Marrow Stromal Cells

17β-estradiol induces the proliferation of hematopoietic stem cells by promoting the osteogenic differentiation of mesenchymal stem cells.

Ginsenoside Rg1 Exerts Estrogen-Like Activities Via Ligand-Independent Activation of ERα Pathway

17 Beta-Estradiol Induces The Proliferation Of Hematopoietic Stem Cells By Promoting The Osteogenic Differentiation Of Mesenchymal Stem Cells

Notoginsenoside R1 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERα/GSK‐3β/β‐catenin signalling pathway

Ginsenoside Re promotes proliferation of murine bone marrow mesenchymal stem cells in vitro through estrogen-like action

Ginsenoside Rg1 modulates PI3K/AKT pathway for enhanced osteogenesis via GPER

Activation of insulin-like growth factor I receptor-mediated pathway by ginsenoside Rg1.

Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.

Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptide-induced human endothelial cells apoptosis.

Estrogenic Effects of Ginsenoside Rg1 in Endometrial Cells in Vitro Were Not Observed in Immature Cd-1 Mice or Ovariectomized Mice Model

Resveratrol Enhances Proliferation and Osteoblastic Differentiation in Human Mesenchymal Stem Cells Via Er-Dependent Erk1/2 Activation

Prostaglandin E2 Mediates Up-regulation of ERRα Expression with BPH-1 Condition Medium in Prostatic Stromal Cells

The Protective Effect of Ginsenoside Rg1 on Rat Bone Marrow Mesenchymal Stem Cell Apoptosis

Ginsenoside Rg3 Inhibits CXCR4 Expression and Related Migrations in a Breast Cancer Cell Line.

Ginsenoside-Rg1 Promote VEGF Production Via Hypoxia-inducible Factor-1 α

G Protein-Coupled Estrogen Receptor Mediates Cell Proliferation through the cAMP/PKA/CREB Pathway in Murine Bone Marrow Mesenchymal Stem Cells

Ginsenoside Rh2 inhibits breast cancer cell growth via<?A3B2 ACK?>ERβ-TNFα pathway

Effects of Ginsenoside Rb1 on Growth of Murine Bone Marrow MSC in Vitro